News

Canada continues solidifying its reputation as a leader in ALS research innovation, as evidenced by the magnitude and quality of conversations, knowledge sharing, and relationship building at the 2024 ALS Canada Research Forum. From April 27 to 29, researchers, industry…

Researchers led by Dr. Michael Strong at Western University in London, Ontario, revealed new data that describes a possible future treatment avenue for ALS. Dr. Strong is a world-renowned scientist and clinician in ALS and one of the key individuals…

Now in its second year, the ALS Society of Canada (ALS Canada), along with Kevin Daly’s friends and colleagues, welcome applications to the post-secondary ALS Canada Kevin Daly Bursary. The $2,500 bursary will be awarded to a post-secondary student whose…

This National Volunteer Week (April 14 – 20), ALS Canada wishes to recognize, celebrate, and thank our incredible volunteers who support our mission, raise funds, and help work toward a world free of ALS. This year’s theme is Every Moment…

This blog series is a place for the ALS community to learn about and stay updated on ALS Canada’s advocacy efforts as well as relevant developments within government. Please note that because ALS Canada advocates federally and provincially within Ontario,…

On Sunday, September 24, cyclists will come together to gear up for change at the third annual ALS Canada Revolution Ride in Dundas, Ontario. Participants come together to build awareness and fundraise in support of people living with amyotrophic…

An announcement of the top-line results from a European phase 3 clinical trial of TUDCA revealed that the primary endpoint of the study was not met as TUDCA failed to demonstrate an ability to significantly alter the progression of ALS…

Amylyx Pharmaceuticals announced that they have started a process with Health Canada to discontinue the marketing authorization for ALBRIOZA. This means that ALBRIOZA will no longer be available for new patients in Canada. People currently on the therapy in Canada…